GET DAILY SIGNALSEmerson Electric (EMR) vs. Kennametal (KMT): Contrasting Paths in Industrial Automation and Materials
Key Takeaways
- Emerson Electric Co. (EMR) is a roughly $90 billion automation and software leader with consistent order growth, while Kennametal Inc. (KMT) is a roughly $2.2 billion tooling and materials specialist whose results hinge heavily on tungsten pricing.
- Recent EMR momentum is supported by durable demand in growth verticals such as semiconductors and power generation, whereas KMT's record quarterly earnings were amplified by a large one-time tungsten price-versus-cost timing benefit.
- EMR generates strong positive free cash flow and recently raised its full-year outlook; KMT swung to negative free operating cash flow as elevated tungsten inventories strained working capital.
- Market positioning diverges sharply: EMR carries a consensus "Buy" rating, while KMT carries a consensus "Sell" rating and has cooled over the past 90 days.
- Tickeron AI Verdict: EMR is the favored ticker of the two based on trend consistency, stability, and the durability of its catalysts.
- For more information on these tickers' major news and today's price moves, explore EMR Major News, EMR Today's Price Move, KMT Major News, and KMT Today's Price Move.
Why These Two Industrials Stand Apart
Industrial stocks often get grouped together by investors, yet their underlying drivers can differ dramatically. This stock comparison examines EMR (Emerson Electric Co.), a large-cap automation and industrial software leader, against KMT (Kennametal Inc.), a smaller-cap maker of tungsten carbide tooling and wear-resistant materials. Both serve manufacturing and industrial end markets, but their business models, growth engines, and recent relative performance have diverged. This comparison is most relevant to investors weighing a diversified, software-leaning industrial franchise against a materials-driven cyclical with higher sensitivity to commodity pricing. Understanding these contrasts can help clarify each company's market positioning and risk profile.
EMR Overview and Recent Performance
Emerson Electric is a global automation leader headquartered in St. Louis, Missouri, delivering measurement instruments, valves, control systems, and industrial software. Its portfolio spans Software & Systems, Intelligent Devices, and Safety & Productivity segments. In recent weeks, EMR has demonstrated consistent momentum, underpinned by broad-based order growth and a healthy backlog. In its most recent quarter, underlying orders rose 7% and underlying sales grew 6%, with the company reporting an $8.2 billion backlog and a book-to-bill ratio of 1.0. Growth verticals advanced 27%, led by a 53% increase in semiconductor demand and a 37% rise in power generation, reflecting investment in grid infrastructure, data centers, and electrification. Management raised its full-year guidance, and analysts broadly maintain a "Buy" consensus. This steady, software-augmented growth trajectory has supported relative strength in the stock. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
KMT Overview and Recent Performance
Kennametal Inc. is an industrial technology company based in Pittsburgh, Pennsylvania, producing tungsten carbides, ceramics, and hard materials across its Metal Cutting and Infrastructure segments. In recent market activity, KMT delivered sharply higher results, with organic sales up 19% for the fiscal year and a record adjusted earnings quarter. However, a large portion of that surge reflected favorable timing between raw-material pricing and costs—approximately $252 million in a single quarter—driven by a historic run-up in tungsten prices. End-market demand was genuinely strong, with energy, earthworks, and aerospace and defense sales all growing substantially. At the same time, the elevated cost of tungsten inventories pushed free operating cash flow into negative territory. This mix of strong reported earnings alongside cash-flow strain and commodity-driven volatility has left sentiment more cautious, with the stock cooling in recent months.
Head-to-Head Comparison
The two companies occupy different tiers of the industrial market. EMR has evolved into a software-heavy automation franchise with recurring-revenue characteristics and secular exposure to semiconductors, power, and digital transformation. Its growth is comparatively diversified and tied to multi-year capital investment cycles. KMT, by contrast, is a materials-science cyclical whose near-term results are disproportionately influenced by a single commodity, tungsten. Its margin and earnings expansion have been meaningful, but a meaningful share of that improvement is non-recurring pricing-timing benefit rather than structural volume growth. On risk factors, EMR faces regional softness in Europe and China and execution considerations around its software portfolio, while KMT contends with raw-material volatility, working-capital pressure, and negative free cash flow. Sentiment reflects these trade-offs: analysts rate EMR a "Buy" and KMT a "Sell," despite KMT's low price-to-earnings multiple.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would currently favor EMR over KMT. The preference is driven by more consistent trend characteristics, a robust and growing backlog, positive free cash flow, and catalysts tied to durable secular themes such as semiconductor capacity and power-grid investment. While KMT has posted impressive headline growth, a substantial portion stems from temporary tungsten pricing dynamics, and its cash-flow strain introduces greater uncertainty. The relative positioning of EMR appears steadier and more repeatable, making it the higher-conviction candidate of the two under current conditions. This assessment is probabilistic and reflects current data rather than a guarantee of future performance.
Using AI Tools in My Analysis
One tool I’ve found useful in this kind of analysis is Tickeron’s AI Trading Bots, which helps evaluate how automated strategies are currently positioned across names like these. It provides a data-driven way to review performance metrics and match bots to prevailing market conditions before committing capital.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
EMR in upward trend: 10-day moving average broke above 50-day moving average on September 29, 2026
The 10-day moving average for EMR crossed bullishly above the 50-day moving average on September 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on EMR as a result. In 62 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for EMR just turned positive on October 27, 2026. Looking at past instances where EMR's MACD turned positive, the stock continued to rise in 30 of 44 cases over the following month. The odds of a continued upward trend are 68%.
Following a +2.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where EMR advanced for three days, in 217 of 345 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 150 of 274 cases where EMR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.
Bearish Trend Analysis
The 10-day RSI Indicator for EMR moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In 17 of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at 40%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EMR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
EMR broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 18 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 30 (best 1 - 100 worst), indicating outstanding price growth. EMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 62 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.515) is normal, around the industry mean (4.038). P/E Ratio (35.935) is within average values for comparable stocks, (37.928). Projected Growth (PEG Ratio) (1.837) is also within normal values, averaging (1.879). Dividend Yield (0.013) settles around the average of (0.030) among similar stocks. P/S Ratio (4.409) is also within normal values, averaging (186.943).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of process controls systems, valves and analytical instruments
Industry IndustrialMachinery
Advertisement